Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

UNLABELLED Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy. METHODS Thirty-seven patients with newly diagnosed LABC underwent (18)F-FDG and (15)O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic (18)F-FDG studies and was expressed as the metabolic rate of (18)F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus (15)O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy. RESULTS Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival. CONCLUSION Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings.

[1]  R. Danieli,et al.  Technetium-99m sestamibi: an indicator of breast cancer invasiveness , 1994, European Journal of Nuclear Medicine.

[2]  B. Teicher.  Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[3]  R. Coleman,et al.  Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. V. Vander Heiden,et al.  Bcl-xL Prevents the Initial Decrease in Mitochondrial Membrane Potential and Subsequent Reactive Oxygen Species Production during Tumor Necrosis Factor Alpha-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[6]  H. Tonami,et al.  FDG PET measurement of the proliferative potential of non-small cell lung cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Mankoff,et al.  Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography , 1999, Cancer.

[8]  A. Cunningham,et al.  Staging in cancer. , 1999, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

[9]  H. Yagata,et al.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.

[10]  B. Leone,et al.  Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1998, The cancer journal from Scientific American.

[11]  M. Mottolese,et al.  Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  S E Harms,et al.  Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging , 1996, Cancer.

[13]  J. Feldman,et al.  Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol‐based ligand‐binding assays , 1996, Cancer.

[14]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[17]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Ellis,et al.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. , 1995, British Journal of Cancer.

[19]  C. Stearns,et al.  Investigation of the count rate performance of the General Electric Advance positron emission tomograph , 1994, Proceedings of 1994 IEEE Nuclear Science Symposium - NSS'94.

[20]  R. Gilles,et al.  Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. , 1994, Radiology.

[21]  D O Cosgrove,et al.  Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. , 1994, Radiology.

[22]  J. Hogg.  Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[23]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Aldrich,et al.  Tumour blood flow: measurement and manipulation for therapeutic gain. , 1993, Cancer treatment reviews.

[25]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[26]  G. Hortobagyi,et al.  Treatment of locally advanced breast cancer. , 1992, Seminars in oncology.

[27]  Q. Han,et al.  [Management of stage III primary breast cancer. An analysis of 221 cases]. , 1992, Zhonghua wai ke za zhi [Chinese journal of surgery].

[28]  A A Lammertsma,et al.  Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. , 1992, Cancer research.

[29]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[30]  I. Ellis,et al.  The value of histological grade in breast cancer experience from a large study with a long term follow up , 1991 .

[31]  R K Jain,et al.  Haemodynamic and transport barriers to the treatment of solid tumours. , 1991, International journal of radiation biology.

[32]  G. Hortobagyi,et al.  Comprehensive management of locally advanced breast cancer , 1990, Cancer.

[33]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[34]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[35]  R. Lyon,et al.  Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. , 1988, Cancer research.

[36]  E. Hoffman,et al.  Validation of PET-acquired input functions for cardiac studies. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  G. Hortobagyi,et al.  Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.

[38]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer (an amendment) , 1978, British Journal of Cancer.

[41]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland , 1977, European journal of cancer.

[42]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[43]  M. Greenwood.  An Introduction to Medical Statistics , 1932, Nature.